3 Penny Stocks Under $900M Market Cap Worth Watching

Major stock indexes in the United States have recently ended lower as concerns about AI valuations and job market data have resurfaced, highlighting the volatility in today's market. Though the term 'penny stock' might sound like a relic of past trading days, the opportunity it points to is still relevant. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Top 10 Penny Stocks In The United States

Click here to see the full list of 368 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Tigo Energy (TYGO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Tigo Energy, Inc., along with its subsidiaries, offers solar and energy storage solutions globally and has a market cap of $152.52 million.

Operations: The company generated $90.78 million in revenue from its Electronic Components & Parts segment.

Market Cap: $152.52M

Tigo Energy, Inc. has shown significant revenue growth with US$30.61 million in Q3 2025 compared to US$14.24 million the previous year, while reducing its net loss from US$13.12 million to US$2.17 million over the same period. The company recently transitioned to digital product documentation via QR codes, enhancing installer support and reducing environmental impact globally. Despite having a high net debt to equity ratio of 57.5%, Tigo maintains sufficient cash runway for over three years due to positive free cash flow growth, although it remains unprofitable with volatile share prices and an inexperienced board of directors.

• Take a closer look at Tigo Energy's potential here in our financial health report.
• Learn about Tigo Energy's future growth trajectory here.

Cytek Biosciences (CTKB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cytek Biosciences, Inc. is a cell analysis solutions company that offers tools to advance biomedical research and clinical applications, with a market cap of approximately $510.17 million.

Operations: There are no specific revenue segments reported for this cell analysis solutions provider.

Market Cap: $510.17M

Cytek Biosciences, Inc. has experienced a challenging financial period, reporting a net loss of US$5.48 million for Q3 2025 despite revenue of US$52.29 million, slightly up from the previous year. The company maintains a strong cash position with short-term assets of US$388.5 million exceeding both short and long-term liabilities, ensuring operational stability without significant shareholder dilution over the past year. Recent strategic initiatives include expanding its European operations and enhancing its reagent business to drive growth and innovation globally, supported by collaborations in advanced flow cytometry technologies for cell therapy manufacturing processes.

• Unlock comprehensive insights into our analysis of Cytek Biosciences stock in this financial health report.
• Gain insights into Cytek Biosciences' outlook and expected performance with our report on the company's earnings estimates.

SES AI (SES)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SES AI Corporation develops and produces AI-enhanced lithium metal and lithium-ion rechargeable battery technologies for various applications including electric vehicles, urban air mobility, drones, robotics, and battery energy storage systems, with a market cap of approximately $813.45 million.

Operations: SES AI Corporation has not reported any revenue segments.

Market Cap: $813.45M

SES AI Corporation, a pre-revenue company with a market cap of US$813.45 million, is focused on developing AI-enhanced battery technologies. Despite its unprofitability and high share price volatility, SES's strong cash position covers both short and long-term liabilities. The company recently raised its 2025 revenue guidance to US$20-25 million due to UZ Energy's contributions and announced a strategic joint venture with Hisun New Energy Materials Ltd., aiming to commercialize novel electrolytes discovered by its Molecular Universe platform. This venture could establish new recurring revenue streams as SES expands its battery materials supply strategies globally.

• Click to explore a detailed breakdown of our findings in SES AI's financial health report.
• Explore SES AI's analyst forecasts in our growth report.

Seize The Opportunity

• Click here to access our complete index of 368 US Penny Stocks.
• Ready To Venture Into Other Investment Styles? These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com